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Background and Importance. In the last eight years temozolomide (TMZ) has been used as the last-line treatment modality for
aggressive pituitary tumors to be applied after the failure of surgery, medical therapy, and radiotherapy.The objective was to achieve
a rapid control of tumor growth and hormone normalization with concurrent chemoradiotherapy in a patient with very aggressive
ACTH pituitary adenoma. Clinical Presentation. We describe a patient with an aggressive ACTH-producing adenoma treated with
concurrent temozolomide and radiotherapy. The patient suffered from an aggressive ACTH adenoma resistant to surgical and
medical treatment. After two months of concurrent temozolomide and radiotherapy, cortisol normalization and significant tumor
shrinkage were observed. After 22 months of follow-up, there is still no evidence of tumor recurrence. Conclusion. Concurrent
treatment with temozolomide and irradiation appears to be highly effective in the achievement of the tumor volume control as well
as in the control of ACTH secretion in aggressive ACTH adenoma.
1. Background and Importance
Pituitary adenomas are common, mostly benign tumors that
are rarely subject to oncological treatment. In symptomatic
or secretory pituitary adenomas the first-line treatment is
the surgical removal of the tumor, which may be followed
by medical therapy if no satisfactory results are achieved by
surgery. Radiation therapy is often part of a multidisciplinary
treatment of functional and nonfunctional tumors, usually
as a third-line treatment after the failure of surgical and/or
medical treatment. Radiotherapy is indicated for recurrent
or progressive tumors after surgery, surgically inaccessible
tumors (e.g., tumors extending to cavernous sinus), and
biochemically uncontrolled tumors after maximal surgical
and medical therapy, and it is also used as the treatment of
choice for patients who are not candidates for surgery.
In the last eight years, temozolomide (TMZ) has increas-
ingly been used as the last-line treatment for aggressive
pituitary tumors resistant to conventional therapy [1–12].
TMZ is an oral alkylating agent approved for the treatment
of glioblastoma. When used for aggressive pituitary tumors,
TMZ is usually given in the conventional scheme including
up to 12 cycles of therapy [13]. We report a case of an
aggressive ACTH-producing pituitary adenoma in which a
combination of radiotherapy and TMZ led to rapid biochem-
ical, radiological, and clinical response.
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Figure 1: Pituitary MRI appearances (T1 postgadolinium weighted sagittal images). (a) After the first transsphenoidal operation for
macrocorticotropinoma in 2010 with a small tumor remnant. (b) Three years after the first operation. Pituitary adenoma with destruction
of the floor of the sella and invasion into sphenoid sinus and both cavernous sinuses. (c) Three months after the initiation of the concurrent
therapy with TMZ and radiotherapy. (d) After the 6 cycles of TMZ. Stable pituitary remnant and biochemical control of the disease.
2. Clinical Presentation
We report a 64-year-old female with Cushing’s disease (CD).
In April 2010, the patient first had a transsphenoidal surgery
of a 15mm large macrocorticotropinoma. The surgery led
to biochemical remission with a presence of a small tumor
remnant (Figure 1(a)). The tumor histology was consistent
with atypical adenoma (Ki-67 20%, no mitoses, p53 not
tested). Two years after the operation, tumor regrowth and
biochemical relapse were observed. Urinary free cortisol
and ACTH levels were 3,400 nmol/dU (NV < 369 nmol/dU)
and 65.3 pmol/l (NV < 16 pmol/L), respectively. MRI con-
firmed tumor progression in sphenoid and ethmoid sinuses,
both cavernous sinuses, with infiltration of the sellar wall,
clivus, and chiasmal compression (Figure 1(b)). The patient
suffered from headaches, visual field deficit, diplopia, oph-
thalmoplegia, and decreased visual acuity. The ketoconazole
treatment was started. Transsphenoidal tumor reduction was
performed, but severe hypercortisolism and ophthalmoplegia
persisted. Postoperative MRI confirmed a large tumor rem-
nant with infiltrative growth pattern destructing the bone
(Figure 1(c)). The tumor tissue was positive for AE1/AE3,
chromogranin, adrenocorticotropic hormone (ACTH), and
growth hormone in some cells. Ki-67 was 10–20% and p53
positivity was present in less than 5% of cells (Figure 2). The
repair enzyme O6-methylguanine-DNA methyltransferase
(MGMT) was not determined. No distant metastases were
found. The patient’s general condition worsened with the
right-side blepharoptosis, progressive visual impairment, and
metabolic disturbances due to severe hypercortisolism.
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Figure 2: (a) HE staining of the pituitary macroadenoma tissue confirming atypical pituitary adenoma (magnification ×100). (b) Ki-67
positivity in tumor tissue of 10–20% (magnification ×400). (c) p53 positivity in less than 5% of cells (magnification ×400).
Due to the rapid growth of the tumor remnant and the
high value of the proliferation marker Ki-67, we decided not
to wait for the effect of radiotherapy, but to immediately
proceed with concurrent chemoradiotherapy (daily radio-
therapy fractions of 2.0Gy to a total dosage of TD 54Gy
concurrent with TMZ 75mg/m2 per day). Radiotherapy
was delivered by the linear accelerator and two opposed
fields of 6/18MV. Gross tumor volume (GTV) was 38.5 cm3
and planning target volume (PTV) 137.7 cm3. After two
weeks, the patient’s vision improved significantly with the
recovery of the blepharoptosis and ophthalmoplegia, but she
started to complain of weakness, dizziness, and fatigue. Low
levels of morning cortisol (55 nmol/L (NR > 330 nmol/L))
were observed indicating biochemical remission of Cushing’s
disease and adrenocortical insufficiency. Ketoconazole was
taken off and replacement therapy with hydrocortisone was
started. The first follow-up MRI performed after 2 months of
chemoradiotherapy showed the reduction of tumor volume
of about 70%. We preceded with adjuvant TMZ in the
dosage of 150mg/m2 in the first cycle (from day 1 to 5) and
200mg/m2 in the following five cycles (from day 1 to 5 every
28 days). The patient was in a significantly better clinical
condition, on hydrocortisone replacement therapy and with-
out major complaints or adverse events. The MRI after 3
and 6 months of therapy showed further tumor regression
(Figure 1(d)). We decided to stop the treatment after 6 cycles
and continued with a close follow- up.The last chemotherapy
cycle was administered in January 2015.The patient tolerated
the treatment very well, except for the fatigue reported from
the beginning. Twenty-two months after the cessation of the
TMZ treatment, the patient is still in remission of CD, with a
stationary volume of the tumor remnant.
3. Discussion
ACTH-producing pituitary adenomas are generally benign
tumors that are usually successfully treated with surgery.
Medical therapy and radiotherapy are used in the case of
surgical failure. In patients with CD, the overall tumor and
hormone control rates in the reported studies are 97% and
74%, respectively, after a median follow-up of 8 years [14].
Fifty percent reduction in the urinary free cortisol level is usu-
ally observed 6 to 12months after radiotherapy. It is estimated
that the normalization of the serum cortisol level in patients
with CD occurs about 24 months after radiotherapy [15]. The
delay in the therapeutic response to radiotherapy is often
unacceptable for some secretory, drug refractory tumors, as
well as for aggressive tumors showing expansive growth.
Temozolomide is an orally available monofunctional
DNA alkylating agent of the imidazotetrazine class. After
spontaneous activation, it preferentially methylates DNA at
N7 positions of guanine in guanine rich regions but also
methylates N3 adenine andO6 guanine.There is a narrow pH
window close to physiological pH at which the whole process
of TMZ prodrug activation can occur. Brain tumors possess
a more alkaline pH compared to surrounding healthy tissue,
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a situation which favors prodrug activation preferentially
within tumor tissue. Methylation results in persistent DNA
strand breaks, causing replication fork collapse. G2/M cell
cycle arrest is triggered, occurring in the second cell cycle
following treatment [16]. BothMGMT activity andmismatch
repair (MMR) status of the tumor are important parameters
that determine sensitivity to temozolomide [17].
In concomitant chemoradiotherapy, temozolomide
reduces the number of cells in tumors undergoing radiation
therapy by their independent cytotoxic action and by
rendering tumor cells more susceptible to killing by ionizing
radiation. Such drugs are potent enhancers of radiation
response and thus might further improve the therapeutic
outcome of chemoradiation therapy. The strategy of
chemoradiation is to exploit the ability of chemotherapeutic
agents to enhance tumor radioresponse. The enhancement
denotes the existence of some type of interaction
between drug and radiation at the molecular, cellular, or
pathophysiologic level resulting in an antitumor effect greater
than would be expected on the basis of additive actions.
Temozolomide makes damaged DNA more susceptible to
radiation damage resulting in enhanced cell killing [18]. In
recent years the use of TMZ has been reported in aggressive
pituitary tumors [1–12]. Raverot et al. reported 18 patients
with ACTH tumors treated with TMZ. After 9.1 ± 4.7 cycles
of therapy, biochemical response, defined as a 50% decrease
in ACTH secretion, was observed in 67% of patients. In the
same study, a reduction in tumor volume, defined as a 20%
decrease in maximal tumor size, was observed in 56% of
patients. According to the results of different studies, tumor
shrinkage or hormonal response to temozolomide treatment
is usually observed within weeks after treatment initiation
in responding patients [19]. Treatment regimens with TMZ
in pituitary tumors are variable, but the one most frequently
used is the conventional regimen with 150–200mg/m2/day
from days 1 to 5 every 28 days [20].
In the majority of the reported cases, TMZ has been used
after the exhaustion of all the three treatment modalities
(surgery, medical therapy, and radiotherapy). However, due
to the rapid tumor growth resulting in the mass effect and
uncontrolled hypercortisolism, we decided to apply a more
aggressive therapeutic strategy using TMZ together with
radiotherapy. Such a treatment regimen is usually applied
in the treatment of high-grade glioma [21], which was the
rationale for the choice of the treatment in the case of
the aggressive pituitary adenoma in question. Besides the
expected synergistic effects of the two different treatment
modalities (TMZ and radiotherapy), a possible disadvantage
of concurrent chemoradiotherapy is that it bears the risk of
increased toxicity and side effects.
In our patient the effect of the combination of TMZ and
radiotherapy was unexpectedly fast and led to rapid tumor
shrinkage as well as to rapid control of hypercortisolism.The
excellent therapeutic response could probably be attributed to
the tumor histology consistent with atypical adenoma char-
acterized by high proliferative indices and rapid cell division.
Until now, there has only been one published case report on
the use of the concurrent radiotherapy andTMZ in an aggres-
sive nonfunctional adenoma, also showing good therapeutic
results [22]. Therefore, we might speculate about the possible
potentiation of the radiation effect by TMZ in aggressive
pituitary adenoma as reported in relation to glioblastomas
[23].Wemight also hypothesize that concurrent chemoradio-
therapy has a promising role in the treatment of selected cases
of rapidly growing, aggressive pituitary corticotropinoma
with high proliferation indices. Since temozolomide has low
toxicity, good tolerability, and two decades of proven efficacy
in other brain tumors, the concurrent chemoradiotherapy
should be considered earlier in the course of the disease.
4. Conclusion
The concurrent use of TMZ and radiotherapy appears to be
a helpful alternative for the treatment of rapidly growing,
aggressive pituitary ACTH-producing adenomas resistant to
conventional treatment.
Competing Interests
The authors declare that they have no competing interests.
References
[1] L. V. Syro, H. Uribe, L. C. Penagos et al., “Antitumour effects
of temozolomide in a man with a large, invasive prolactin-
producing pituitary neoplasm,” Clinical Endocrinology, vol. 65,
no. 4, pp. 552–553, 2006.
[2] T. H. Dillard, S. H. Gultekin, J. B. Delashaw Jr., C. G. Yedinak, E.
A. Neuwelt, and M. Fleseriu, “Temozolomide for corticotroph
pituitary adenomas refractory to standard therapy,” Pituitary,
vol. 14, no. 1, pp. 80–91, 2011.
[3] A. K. Annamalai, A. F. Dean, N. Kandasamy et al., “Temozolo-
mide responsiveness in aggressive corticotroph tumours: a case
report and review of the literature,” Pituitary, vol. 15, no. 3, pp.
276–287, 2012.
[4] Z. M. Bush, J. A. Longtine, T. Cunningham et al., “Temo-
zolomide treatment for aggressive pituitary tumors: correlation
of clinical outcome with O6-methylguanine methyltransferase
(MGMT) promoter methylation and expression,” Journal of
Clinical Endocrinology andMetabolism, vol. 95, no. 11, pp. E280–
E290, 2010.
[5] M. Losa, E. Mazza, M. R. Terreni et al., “Salvage therapy
with temozolomide in patients with aggressive or metastatic
pituitary adenomas: experience in six cases,” European Journal
of Endocrinology, vol. 163, no. 6, pp. 843–851, 2010.
[6] V. J. Moyes, G. Alusi, H. I. Sabin et al., “Treatment of Nelson’s
syndromewith temozolomide,”European Journal of Endocrinol-
ogy, vol. 160, no. 1, pp. 115–119, 2009.
[7] S. Mohammed, K. Kovacs, W. Mason, H. Smyth, and M.
D. Cusimano, “Use of temozolomide in aggressive pituitary
tumors: case report,” Neurosurgery, vol. 64, no. 4, pp. E773–
E774, 2009.
[8] D. Bengtsson, H. D. Schrøder, M. Andersen et al., “Long-term
outcome andMGMT as a predictive marker in 24 patients with
atypical pituitary adenomas and pituitary carcinomas given
treatment with temozolomide,” Journal of Clinical Endocrinol-
ogy and Metabolism, vol. 100, no. 4, pp. 1689–1698, 2015.
[9] C. E. Fadul, A. L. Kominsky, L. P. Meyer et al., “Long-term
response of pituitary carcinoma to temozolomide. Report of
Case Reports in Endocrinology 5
two cases,” Journal of Neurosurgery, vol. 105, no. 4, pp. 621–626,
2006.
[10] B. C. Whitelaw, D. Dworakowska, N. W. Thomas et al., “Temo-
zolomide in the management of dopamine agonist-resistant
prolactinomas,” Clinical Endocrinology, vol. 76, no. 6, pp. 877–
886, 2012.
[11] M. Campdera´, N. Palacios, J. Aller et al., “Temozolomide for
aggressive ACTH pituitary tumors: failure of a second course
of treatment,” Pituitary, vol. 19, no. 2, pp. 158–166, 2016.
[12] I. Zemmoura, A. Wierinckx, A. Vasiljevic, M. Jan, J. Trouillas,
and P. Franc¸ois, “Aggressive and malignant prolactin pituitary
tumors: pathological diagnosis and patient management,” Pitu-
itary, vol. 16, no. 4, pp. 515–522, 2013.
[13] G. Raverot, N. Sturm, F. De Fraipont et al., “Temozolomide
treatment in aggressive pituitary tumors and pituitary carci-
nomas: a French multicenter experience,” Journal of Clinical
Endocrinology and Metabolism, vol. 95, no. 10, pp. 4592–4599,
2010.
[14] T. Ajithkumar andM. Brada, “Pituitary radiotherapy,” inOxford
Textbook of Endocrinology and Diabetes, J. A. Wass, S. A. Amiel,
and M. C. Davies, Eds., Oxford University Press, Oxford, UK,
2011.
[15] G. Minniti, M. Osti, M. L. Jaffrain-Rea, V. Esposito, G. Can-
tore, and R. Maurizi Enrici, “Long-term follow-up results of
postoperative radiation therapy for Cushing’s disease,” Journal
of Neuro-Oncology, vol. 84, no. 1, pp. 79–84, 2007.
[16] J. Zhang,M. F. G. Stevens, and T. D. Bradshaw, “Temozolomide:
mechanisms of action, repair and resistance,”CurrentMolecular
Pharmacology, vol. 5, no. 1, pp. 102–114, 2012.
[17] A. Thomas, M. Tanaka, J. Trepel, W. C. Reinhold, V. N.
Rajapakse, and Y. Pommier, “Temozolomide in the era of
precisionmedicine,”Cancer Research, vol. 77, no. 4, pp. 823–826,
2017.
[18] H. Choy, R. Macre, and L. Milas, “Basic concepts of chemother-
apy and irradiation interaction,” in Principles and Practice of
Radiation Oncology, A. Perez, L. W. Brady, E. C. Halperin, and
R. K. Schmidt-Ullrich, Eds., pp. 736–756, Lippincot Williams
and Wilkins, Philadelphia, Pa, USA, 2004.
[19] G. Raverot, F. Castinetti, E. Jouanneau et al., “Pituitary carci-
nomas and aggressive pituitary tumours: merits and pitfalls of
temozolomide treatment,” Clinical Endocrinology, vol. 76, no. 6,
pp. 769–775, 2012.
[20] M. Bower, E. S. Newlands, N. M. Bleehen et al., “Multicentre
CRC phase II trial of temozolomide in recurrent or progressive
high-grade glioma,” Cancer Chemotherapy and Pharmacology,
vol. 40, no. 6, pp. 484–488, 1997.
[21] R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Radiotherapy
plus concomitant and adjuvant temozolomide for glioblas-
toma,” New England Journal of Medicine, vol. 352, no. 10, pp.
987–996, 2005.
[22] C. Zhong, S. Yin, P. Zhou, and S. Jiang, “Pituitary atypical
adenoma or carcinoma sensitive to temozolomide combined
with radiation therapy: a case report of early identification and
management,”Turkish Neurosurgery, vol. 24, no. 6, pp. 963–966,
2014.
[23] D. J. Sher, J. W. Henson, B. Avutu et al., “The added value
of concurrently administered temozolomide versus adjuvant
temozolomide alone in newly diagnosed glioblastoma,” Journal
of Neuro-Oncology, vol. 88, no. 1, pp. 43–50, 2008.
